Treatment of lung cancer
- PMID: 22974781
- DOI: 10.1016/j.rcl.2012.06.003
Treatment of lung cancer
Abstract
Lung cancer is a heterogenous disease with 2 main subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Early-stage NSCLC is managed primarily by surgical resection, with adjuvant chemotherapy for selected patients with stage IB, II, and III disease. Patients with locally advanced stage III NSCLC are usually treated with combined modality therapy. Advanced NSCLC remains an incurable disease. Further advances will rely on improvements in understanding of the molecular events driving the malignant phenotype and the development of novel, targeted therapeutic strategies.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
[Combined-modality therapy for lung cancer].Nihon Rinsho. 2010 Jun;68(6):1121-8. Nihon Rinsho. 2010. PMID: 20535966 Review. Japanese.
-
Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.Clin Lung Cancer. 2004 Sep;6(2):85-98. doi: 10.3816/CLC.2004.n.022. Clin Lung Cancer. 2004. PMID: 15476594 Review.
-
Treatment of advanced (stages III and IV) non-small-cell lung cancer.Curr Probl Cancer. 1998 Mar-Apr;22(2):85-132. doi: 10.1016/s0147-0272(98)90010-1. Curr Probl Cancer. 1998. PMID: 9580849 Review.
-
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.Lancet Oncol. 2009 Aug;10(8):785-93. doi: 10.1016/S1470-2045(09)70172-X. Epub 2009 Jul 13. Lancet Oncol. 2009. PMID: 19604722 Clinical Trial.
-
[Combined modality therapy for small cell lung cancer patient with limited stage disease].Zhonghua Zhong Liu Za Zhi. 2007 Sep;29(9):701-3. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 18246803 Chinese.
Cited by
-
Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells.Oncotarget. 2020 Apr 21;11(16):1399-1416. doi: 10.18632/oncotarget.27519. eCollection 2020 Apr 21. Oncotarget. 2020. PMID: 32362998 Free PMC article.
-
SLC7A5 is a lung adenocarcinoma-specific prognostic biomarker and participates in forming immunosuppressive tumor microenvironment.Heliyon. 2022 Oct 2;8(10):e10866. doi: 10.1016/j.heliyon.2022.e10866. eCollection 2022 Oct. Heliyon. 2022. PMID: 36217463 Free PMC article.
-
A new PET/CT volumetric prognostic index for non-small cell lung cancer.Lung Cancer. 2015 Jul;89(1):43-9. doi: 10.1016/j.lungcan.2015.03.023. Epub 2015 Apr 9. Lung Cancer. 2015. PMID: 25936471 Free PMC article.
-
Potential of Nanotechnology-based Formulations in Combating Pulmonary Infectious Diseases: A Current Scenario.Curr Pharm Des. 2022;28(42):3413-3427. doi: 10.2174/1381612829666221116143138. Curr Pharm Des. 2022. PMID: 36397631 Review.
-
Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients.Oncotarget. 2016 Apr 5;7(14):17442-54. doi: 10.18632/oncotarget.7856. Oncotarget. 2016. PMID: 26943581 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical